FDA approves for launch of another psoriasis treatment
-
Last Update: 2020-06-10
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
psoriasis is an inflammatory diseaseIn the United States, there are about 7.5 million psoriasis patients, 80 percent of whom suffer from plaque psoriasisrecently, the U.SFDA(http://approved abbreviated the treatment of skyrizizumab, a heavy-duty psoriasis treatment, for patients with moderately severe psoriasisand today, the FDA approved another psoriasis treatment, Duobrii from Ortho Dermatologics, the skin disease business of Bausch Health CompaniesAs an external lotion, Duobrii is expected to bring new treatments to patientsSpecifically, the treatment consists of halobetasol propionate (0.01%) and his zarodine (tazarotene, 0.045%)the former is a class of corticosteroids that bind to corticosteroid receptors to fight inflammation, while the latter is a precursordrug(http://, which has previously been approved to treat skin diseases such as acne and psoriasisIt is worth mentioning that this is also the only treatment that is currently formed by a special combination of these two drugsThe effectiveness and safety of the therapy have been evaluated and validated in a number of clinicallytrial(http://A Phase 2 clinical trial showed that the emulsion was better treated than its active ingredients alone, suggesting that the two ingredients could achieve synergistic results in one formulain three Phase 3 clinical trials, the effectiveness of the treatment was again proven and short-term and long-term safety assessed
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
